BioWorld

May 2, 2005

Money Raised Year To Date

Stock Winners and Losers For The Week

Collaborations Between Biotech And Pharmaceutical Companies: New Agreements, Feb. 24-April 28, 2005#

Manufacturing, Marketing And Distribution Agreements Between Biotech And Pharmaceutical Companies: Feb. 24-April 27, 2005#

Adventrx's Biomodulator Adds Weaponry To Cancer Arsenal

Say "chemotherapy" and most people cringe, conjuring a mental picture of a sunken-eyed, hairless cancer patient who vomits constantly, breaks out in a rash and stays indoors to avoid the bright light of day. Read More

Biotech - Big Pharma Collaborations: Modified And Terminated Agreements, Feb. 24-April 27, 2005#

BioWorld Stock Report For Public Biotechnology Companies

Today's news in brief

BioWorld

BioWorld briefs for Dec. 12, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 12, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Illustration of head with maze that is missing parts

CTAD 2025: The challenges of combination therapies for dementia

BioWorld Science

At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...

DEE-lightful: Praxis’ phase II results allow stock to flex its muscle

BioWorld

Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...